Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.

× No keyword cloud information.

52 in total

Review 1. Neurotoxicity of biologically targeted agents in pediatric cancer trials.

Authors: Elizabeth M Wells; Amulya A Nageswara Rao; Joseph Scafidi; Roger J Packer
Journal: Pediatr Neurol Date: 2012-04 Impact factor: 3.372

Review 2. [Neurological complications of neurooncological therapy].

Authors: U Herrlinger; J P Steinbach
Journal: Nervenarzt Date: 2010-08 Impact factor: 1.214

Review 3. The risk for anemia with targeted therapies for solid tumors.

Authors: Sandro Barni; Mary Cabiddu; Paolo Guarneri; Veronica Lonati; Fausto Petrelli
Journal: Oncologist Date: 2012-04-24

Review 4. Thrombotic microangiopathy with targeted cancer agents.

Authors: John A Blake-Haskins; Robert J Lechleider; Robert J Kreitman
Journal: Clin Cancer Res Date: 2011-08-03 Impact factor: 12.531

5. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.

Authors: Erkan Dogan; Sercan Aksoy; Cagatay Arslan; Didem S Dede; Kadri Altundag
Journal: Med Oncol Date: 2010-12 Impact factor: 3.064

Review 6. Adverse effects of anticancer agents that target the VEGF pathway.

Authors: Helen X Chen; Jessica N Cleck
Journal: Nat Rev Clin Oncol Date: 2009-07-07 Impact factor: 66.675

7. Posterior reversible encephalopathy syndrome in cancer patients: a single institution retrospective study.

Authors: Carlos Kamiya-Matsuoka; Asif M Paker; Linda Chi; Ayda Youssef; Sudhakar Tummala; Monica E Loghin
Journal: J Neurooncol Date: 2016-02-22 Impact factor: 4.130

Review 8. Chemotherapy-associated renal dysfunction.

Authors: Vaibhav Sahni; Devasmita Choudhury; Ziauddin Ahmed
Journal: Nat Rev Nephrol Date: 2009-06-30 Impact factor: 28.314

Review 9. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms.

Authors: Richard G Abramson; Vandana G Abramson; Emily Chan; Leora Horn; Vicki L Keedy; William Pao; Jeffrey A Sosman
Journal: AJR Am J Roentgenol Date: 2013-03 Impact factor: 3.959

10. A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.

Authors: R J Schilder; M W Sill; H A Lankes; M A Gold; R S Mannel; S C Modesitt; P Hanjani; A J Bonebrake; A K Sood; A K Godwin; W Hu; R K Alpaugh
Journal: Gynecol Oncol Date: 2013-01-13 Impact factor: 5.482